Home » Newsletters » BioWorld Science

BioWorld Science

March 10, 2009

View Archived Issues

VCL-CT02 primes safely for anamnestic response to Towne strain vaccine

Boeringer Ingelheim presents novel hepatitis C virus polymerase inhibitors

Roche patents novel dual 5-HT2A/D3 receptor modulators

High-dose fenretinide displays limited antitumor activity in prostate cancer

AstraZeneca claims pyridinyloxy pyridines as activin receptor-like kinase 5 inhibitors

Merck & Co. presents novel pyridine carboxamide orexin receptor antagonists

Abiraterone acetate plus prednisone show antitumor activity in prostate cancer

Abbott presents novel 5-HT6 receptor ligands

Novel bronchodilating isoquinoline amides described by Respiratorius

Tramadol decreases spinal cord injury pain in humans but shows severe side effects

AndroScience announces phase IIa study results for ASC-J9 in acne

AEterna Zentaris and sanofi-aventis sign agreement for cetrorelix in U.S. market

GlaxoSmithKline reviews highlights of 2008

Merck & Co. to merge with Schering-Plough

Surface Logix raises financing and starts phase IIb SLx-4090 trial in diabetes

GTC Biotherapeutics receives milestone for progress in ATryn program

HGS reports positive results in second phase III trial of Albuferon in HCV

Forest and Cypress revise timing of launch for fibromyalgia drug Savella

Genfit and sanofi-aventis sign two-year extension to 1999 partnership agreement

FDA requests additional confirmatory trial for Genta's Genasense NDA in CLL

Isis acquires common shares and warrants representing 17.2% of iCo Therapeutics

SciClone completes enrollment in phase II clinical trial of RP-101 in pancreatic cancer

Pluristem presents update on preparations for German clinical trial of PLX-PAD in CLI

FDA approves SyntheMed's Repel-CV in pediatric cardiac surgery

Evotec and Roche collaborate for EVT-101 for treatment-resistant depression

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...